NasdaqHealth CareHealth Care EquipmentS&P SmallCap 600
$7.33
-0.08 (-1.08%)
Close of Nov 06, 2026 · end-of-day data
AHCO 8-K filings, explained
Every material Form 8-K AdaptHealth has filed with the SEC since October 22, 2024, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
AdaptHealth reported third-quarter 2026 net revenue of $745.6 million, up 10.9% from a year earlier, but a $184.8 million pre-tax goodwill write-down produced a net loss. The company raised its full-year 2026 revenue and Adjusted EBITDA guidance but lowered its free cash flow guidance, and it cleared the Hart-Scott-Rodino waiting period for the pending $235.0 million sale of its Diabetes Health business.
Q3 net revenue $745.6 million vs. $672.4 million; organic revenue growth of 12.8%
Q3 Adjusted EBITDA $141.9 million vs. $146.1 million, down 2.9%
2026 guidance: revenue raised to $2.88-$2.90 billion; Adjusted EBITDA raised to $510-$525 million; free cash flow cut to $50-$75 million from $80-$120 million
Diabetes Health sale for $235.0 million in cash expected to close in early 2027
AdaptHealth appointed Harriss Currie as Chief Financial Officer, effective September 9, 2026. Jason Clemens, the current CFO, ends his CFO authority on September 8, 2026, and leaves the company effective October 1, 2026, with severance for a termination without cause. The change in the top finance role is a leadership transition; the filing contains no financial results or guidance.
Harriss Currie, age 64, starts as CFO on September 9, 2026, under an employment agreement dated September 7, 2026.
Currie's annual base salary is $670,000, with a target bonus of 100% of base salary, and a sign-on RSU grant valued at $818,462.
Currie previously served as CFO of Luminex Corp. from October 2003 until its sale to DiaSorin in July 2021.
Jason Clemens's CFO authority ends September 8, 2026, and his employment ends October 1, 2026; he will receive severance for a termination without cause.
AdaptHealth reported second-quarter 2026 net revenue of $740.3 million, up 12.7% from a year earlier, but recorded a $144.2 million goodwill impairment and a net loss attributable to the company. The company also lowered its fiscal 2026 adjusted EBITDA guidance to $490 million to $520 million from $680 million to $730 million, citing a West Coast capitated contract, a manufacturer price increase and portfolio changes, which weighs on shareholders' earnings outlook.
Q2 net revenue was $740.3 million versus $657.1 million, an increase of 12.7%; organic revenue grew 15.9%.
Goodwill impairment of $144.2 million drove a net loss; adjusted EBITDA was $132.0 million versus $136.4 million, down 3.2%.
Fiscal 2026 adjusted EBITDA guidance is $490 million to $520 million; the revision includes a $100 million impact from the Diabetes Health discontinued operations, a $55 million West Coast contract impact and a $30 million manufacturer pric
AdaptHealth agreed in July 2026 to sell its Diabetes Health business for $235.0 million in cash, subject to customary purchase price adjustments.
AdaptHealth agreed on July 19, 2026 to sell substantially all assets of its Diabetes Health business to RGH Enterprises, a subsidiary of Cardinal Health, for $235.0 million in cash, subject to a working capital adjustment. The company says the sale lets it redeploy capital to core sleep and respiratory businesses and reduce debt, but it has not yet disclosed the financial effect, which it will cover on its August 4, 2026 earnings call.
Purchase price is $235.0 million in cash, with $8.0 million and $18.8 million placed in escrow at closing for price adjustment and indemnification obligations
Closing requires Hart-Scott-Rodino antitrust clearance and other customary conditions; either party may terminate if closing has not occurred within twelve months, and a $9.4 million termination fee applies in certain antitrust failure case
AdaptHealth agreed to a four-year non-compete in North America following closing
Company will discuss financial and guidance effects, including discontinued operations treatment, on its Q2 2026 earnings call on August 4, 2026
AdaptHealth said a threat actor gained unauthorized access to certain cloud-based business applications, including patient management and document storage systems, and exfiltrated some data. The company determined on June 27, 2026 that the incident is material, and said it has contained the threat and that operations and patient service have not been materially affected. The full financial impact, data scope and volume remain undetermined, and the company says cybersecurity insurance may cover some losses.
Threat actor contacted the company on June 15, 2026, claiming to have obtained data from its systems
Affected data includes insurance billing passwords and certain patient personally identifiable and protected health information
Company does not collect Social Security numbers or store financial account or payment card data in the affected systems
Company says it cannot yet determine the full financial impact and will amend the filing as information becomes available
AdaptHealth reported first-quarter 2026 net revenue of $819.8 million, up 5.4%, and raised its full-year 2026 net revenue guidance by $10 million. Net loss attributable to the company widened to $16.0 million from $7.2 million, and Adjusted EBITDA fell 5.3% to $121.2 million, so revenue gains came with lower profitability. The company also replaced its Chief Operating Officer.
Q1 2026 net revenue $819.8 million vs. $777.9 million; organic revenue growth 9.1%
Net loss attributable to AdaptHealth $16.0 million (diluted EPS -$0.12) vs. $7.2 million (-$0.05)
Adjusted EBITDA $121.2 million vs. $127.9 million; free cash flow negative $27.5 million
FY2026 net revenue guidance raised to $3.45 billion-$3.52 billion; Adjusted EBITDA ($680 million-$730 million) and free cash flow ($175 million-$225 million) guidance maintained
AdaptHealth and its subsidiary AdaptHealth LLC entered a credit agreement dated April 10, 2026, with Bank of America as administrative agent, and used it to repay the prior credit agreement from January 20, 2021. The new facility provides $450 million of revolving commitments, $325 million of initial term loans and $325 million of delayed draw term loans, and matures in April 2031. The company says the new terms carry lower pricing, and it does not expect the transaction to affect its full-year 2026 guidance.
Facility includes $450 million in revolving commitments, $325 million in initial term loans and $325 million in delayed draw term loans available for up to two years after closing.
Credit agreement dated April 10, 2026; scheduled maturity April 13, 2031, subject to a springing maturity 91 days before the 2028 Senior Notes mature if more than $15 million remains outstanding.
Proceeds repaid the prior credit agreement with Regions Bank; the company says the lowest pricing tier fell from 1.50% to 1.125% over SOFR.
The company does not expect the transaction to affect full-year 2026 guidance issued February 24, 2026.
AdaptHealth reported fourth-quarter 2025 net revenue of $846.3 million, down 1.2%, and a net loss attributable to the company of $102.8 million, compared with net income of $50.3 million a year earlier. The loss includes a non-cash goodwill impairment charge of $128.0 million, and Adjusted EBITDA fell 18.7% to $163.1 million. The company also issued 2026 guidance of $3.44 billion to $3.51 billion in net revenue and $680 million to $730 million in Adjusted EBITDA.
Q4 2025 net revenue was $846.3 million, down from $856.6 million; Adjusted EBITDA was $163.1 million, down from $200.6 million.
Q4 2025 net loss attributable to AdaptHealth was $102.8 million, including a $128.0 million non-cash goodwill impairment tied to the Diabetes Health unit.
Full-year 2025 net loss attributable to AdaptHealth was $70.8 million, versus net income of $90.4 million in 2024.
2026 guidance: net revenue of $3.44 billion to $3.51 billion, Adjusted EBITDA of $680 million to $730 million, and free cash flow of $175 million to $225 million.
AdaptHealth reported third-quarter 2025 results for the period ended September 30, 2025, with net revenue of $820.3 million, up 1.8% from $805.9 million a year earlier, and adjusted EBITDA of $170.1 million, up 3.5%. The company kept its fiscal 2025 guidance unchanged, including net revenue of $3.18 billion to $3.26 billion and adjusted EBITDA of $642 million to $682 million, and reported that net leverage was 2.68x against a 2.50x target.
Q3 net income attributable to AdaptHealth was $24.5 million, compared with $22.9 million a year earlier.
Q3 organic revenue growth was 5.1%, the highest since the first quarter of 2024, per the company.
Fiscal 2025 guidance maintained: net revenue $3.18 billion to $3.26 billion; free cash flow $170 million to $190 million.
Nine-month net income attributable to AdaptHealth was $32.0 million, down from $40.2 million, and nine-month free cash flow was $140.1 million, down from $162.7 million.
AdaptHealth reported second quarter 2025 net revenue of $800.4 million, down 0.7% from $806.0 million, and net income attributable to the company of $14.7 million, down from $19.4 million. The company lowered its full-year 2025 Adjusted EBITDA guidance to $642 million to $682 million from $662 million to $702 million, which matters to shareholders because both headline profit and the outlook weakened.
Net revenue was $800.4 million versus $806.0 million a year earlier, a decrease of 0.7%.
Adjusted EBITDA was $155.5 million versus $165.3 million, a decrease of 5.9%.
Full-year 2025 Adjusted EBITDA guidance was lowered to $642 million to $682 million from $662 million to $702 million.
Full-year 2025 net revenue guidance was narrowed to $3.18 billion to $3.26 billion from $3.15 billion to $3.29 billion; free cash flow guidance of $170 million to $190 million was unchanged.
AdaptHealth reported first-quarter 2025 net revenue of $777.9 million, down 1.8% from a year earlier, and a net loss attributable to the company of $7.2 million, compared with a $2.1 million loss in the prior-year quarter. Adjusted EBITDA fell 19.3% to $127.9 million. The company also lowered its fiscal 2025 net revenue and adjusted EBITDA guidance to account for the disposition of certain incontinence assets, reducing its outlook for shareholders.
Net revenue was $777.9 million, down from $792.5 million in the first quarter of 2024, a decrease of 1.8%.
Net loss attributable to AdaptHealth Corp. was $7.2 million, compared with a net loss of $2.1 million a year earlier.
Fiscal 2025 net revenue guidance was lowered to $3.18 billion to $3.32 billion from $3.22 billion to $3.36 billion; adjusted EBITDA guidance was lowered to $665 million to $705 million from $670 million to $710 million.
Free cash flow guidance of $180 million to $220 million was unchanged; first-quarter cash flow from operations was $95.5 million.
AdaptHealth reported fourth-quarter and full-year 2024 results on February 25, 2025, and gave 2025 guidance. Fourth-quarter net revenue and adjusted EBITDA each fell slightly from the prior-year quarter, while full-year net revenue and adjusted EBITDA rose, and net income swung to a profit of $90.4 million from a loss of $678.9 million. The company's 2025 guidance calls for net revenue of $3.22 billion to $3.36 billion and adjusted EBITDA of $670 million to $710 million.
Q4 2024 net revenue was $856.6 million, down 0.2% from $858.2 million; Q4 adjusted EBITDA was $200.6 million, down 2.0%.
Full-year 2024 net revenue was $3.26 billion, up 1.9%, and adjusted EBITDA was $688.7 million, up 2.7%.
Full-year 2024 net income attributable to AdaptHealth was $90.4 million, compared with a loss of $678.9 million in 2023, which included an $830.8 million goodwill impairment.
2025 guidance: net revenue of $3.22 billion to $3.36 billion, adjusted EBITDA of $670 million to $710 million, and free cash flow of $180 million to $220 million.
On December 9, 2024, AdaptHealth amended the transition, separation and release agreement with Shaw Rietkerk, its Chief Business Officer, reducing his annual base salary from $500,000 to $125,000 starting January 1, 2025. The filing describes a compensation change for one officer and does not state any effect on the company's financial results.
Amendment dated December 9, 2024, to a transition, separation and release agreement dated August 21, 2024
Annual base salary reduced from $500,000 to $125,000, effective January 1, 2025
Full amendment filed as Exhibit 10.1; the 8-K was signed by CFO Jason Clemens on December 13, 2024
AdaptHealth reported third-quarter 2024 net revenue of $805.9 million, up 0.2%, and net income attributable to the company of $22.9 million, compared with a net loss of $454.1 million a year earlier. The company lowered its 2024 net revenue and adjusted EBITDA guidance while raising its free cash flow guidance, so results and outlook point in different directions for shareholders.
Net revenue was $805.9 million versus $804.0 million, and adjusted EBITDA was $164.3 million versus $161.2 million, up 1.9%.
Net income attributable to AdaptHealth was $22.9 million, compared with a net loss of $454.1 million in the prior-year quarter, which included a $511.9 million goodwill impairment.
2024 net revenue guidance was lowered to $3.220 billion to $3.260 billion from $3.255 billion to $3.315 billion.
2024 adjusted EBITDA guidance was lowered to $655 million to $675 million from $660 million to $700 million; free cash flow guidance was raised to $175 million to $195 million from $160 million to $180 million.
AdaptHealth Corp. entered into a new employment agreement with Chief Technology Officer Albert Prast on October 30, 2024, superseding his July 24, 2023 agreement. The filing sets a $450,000 base salary, a target bonus of 100% of base salary, and severance terms if he is terminated without cause or resigns for good reason. The filing contains no financial results, and the terms are a routine compensation update for a senior officer.
Base salary of $450,000 with a target annual bonus equal to 100% of base salary
Severance on a qualifying termination includes 18 months of base salary continuation and up to 18 months of COBRA health coverage
Equity awards eligible from 2025 under the Second Amended and Restated 2019 Stock Incentive Plan
Non-compete applies for 18 months after employment ends; non-solicit for 24 months
AdaptHealth Corp. appointed Diana L. Nole to its Board of Directors effective October 16, 2024, as a Class I director, and the Board has determined she is independent under SEC and Nasdaq rules. Ms. Nole previously served as Executive Vice President and General Manager of the Healthcare Division of Nuance Communications, and the appointment adds a director with healthcare technology experience to the Board.
Diana L. Nole, age 59, appointed to the Board effective October 16, 2024; term runs until the 2026 annual meeting
Served as EVP and General Manager of Nuance Communications' Healthcare Division from June 1, 2020 to October 4, 2024
Company entered into an indemnification agreement with Ms. Nole on October 16, 2024; she receives the same non-employee director compensation, pro-rated for the current year
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every AdaptHealth filing is on SEC EDGAR ↗. 8-K briefs of other companies →